DOP2018000284A - Anticuerpos antifactor de la coagulación xi - Google Patents

Anticuerpos antifactor de la coagulación xi

Info

Publication number
DOP2018000284A
DOP2018000284A DO2018000284A DO2018000284A DOP2018000284A DO P2018000284 A DOP2018000284 A DO P2018000284A DO 2018000284 A DO2018000284 A DO 2018000284A DO 2018000284 A DO2018000284 A DO 2018000284A DO P2018000284 A DOP2018000284 A DO P2018000284A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
body coagulation
fxi
activation
coagulation antibodies
Prior art date
Application number
DO2018000284A
Other languages
English (en)
Spanish (es)
Inventor
Chen Zhu
P Ellsworth Kenneth
Milligan James
Oldham Elizabeth
Seiffert Dietmar
Ganti Vaishnavi
Tabrizifard Mohammad
Prinz Bianka
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of DOP2018000284A publication Critical patent/DOP2018000284A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
DO2018000284A 2016-06-14 2018-12-13 Anticuerpos antifactor de la coagulación xi DOP2018000284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14

Publications (1)

Publication Number Publication Date
DOP2018000284A true DOP2018000284A (es) 2019-01-31

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000284A DOP2018000284A (es) 2016-06-14 2018-12-13 Anticuerpos antifactor de la coagulación xi

Country Status (29)

Country Link
US (6) US10676536B2 (cg-RX-API-DMAC7.html)
EP (1) EP3469002A1 (cg-RX-API-DMAC7.html)
JP (2) JP7022081B2 (cg-RX-API-DMAC7.html)
KR (2) KR102218714B1 (cg-RX-API-DMAC7.html)
CN (2) CN116425879A (cg-RX-API-DMAC7.html)
AR (1) AR108717A1 (cg-RX-API-DMAC7.html)
AU (3) AU2017286432B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075858A2 (cg-RX-API-DMAC7.html)
CA (2) CA3025869C (cg-RX-API-DMAC7.html)
CL (2) CL2018003565A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018013434A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180583A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000284A (cg-RX-API-DMAC7.html)
EA (1) EA201892716A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18091593A (cg-RX-API-DMAC7.html)
GE (1) GEP20227382B (cg-RX-API-DMAC7.html)
IL (2) IL315266A (cg-RX-API-DMAC7.html)
JO (1) JOP20180121A1 (cg-RX-API-DMAC7.html)
MA (1) MA45234A (cg-RX-API-DMAC7.html)
MX (2) MX2018015757A (cg-RX-API-DMAC7.html)
MY (1) MY201852A (cg-RX-API-DMAC7.html)
NI (1) NI201800134A (cg-RX-API-DMAC7.html)
PE (1) PE20190416A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502586A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201810763TA (cg-RX-API-DMAC7.html)
TN (1) TN2018000417A1 (cg-RX-API-DMAC7.html)
TW (2) TWI752964B (cg-RX-API-DMAC7.html)
UA (1) UA129793C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017218371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017218371A1 (en) * 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
KR20230034361A (ko) * 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
EP4177275A4 (en) * 2020-07-03 2024-07-17 Suzhou Alphamab Co., Ltd COAGULATION FACTOR XI (FXI)-BINDING PROTEIN
WO2022171656A1 (en) * 2021-02-09 2022-08-18 Arxx Therapeutics As Anti-s100a4 humanized antibodies, uses and methods
WO2023098637A1 (zh) * 2021-11-30 2023-06-08 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
TWI382031B (zh) 2003-07-15 2013-01-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
KR20090024745A (ko) 2006-06-06 2009-03-09 크루셀 홀란드 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
DK3002298T3 (da) 2007-11-21 2019-10-28 Univ Oregon Health & Science Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
HRP20181727T1 (hr) * 2008-06-19 2019-02-08 Prothix Bv Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
EP2313434A4 (en) 2008-07-31 2013-03-27 Univ California ANTIBODIES FOR NEUTRALIZING BOTULINE NEUROTOXINES
SI2350304T1 (sl) 2008-10-31 2017-04-26 Janssen Biotech, Inc. Antagonisti toll-u podobnega receptorja
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
CA2747519C (en) 2008-12-18 2019-04-02 Oregon Health & Science University Anti-fxi antibodies and methods of use
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
EP2949673A1 (en) 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anti-il-3ra antibody for use in treatment of blood tumor
EP2488553B1 (en) 2009-10-12 2015-06-17 Pfizer Inc. Cancer treatment
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
ES2776980T3 (es) 2009-12-23 2020-08-03 Merck Sharp & Dohme Línea celular 3M
JP2013519164A (ja) * 2010-02-03 2013-05-23 トリロジー アイピー ホールディングス，インコーポレイテッド モバイル通信プラン提供
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CN103874707B (zh) 2010-11-19 2017-04-19 卫材R&D管理有限公司 中和抗‑ccl20抗体
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
JP6141834B2 (ja) 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
DK2650310T3 (en) 2012-04-13 2016-09-12 Rottapharm Biotech Srl The anti-ADAMTS-5 antibody, derivatives and uses thereof
HUE040580T2 (hu) * 2012-05-10 2019-03-28 Bayer Pharma AG XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk
US9944707B2 (en) 2012-05-17 2018-04-17 Sorrento Therapeutics, Inc. Antibodies that bind epidermal growth factor receptor (EGFR)
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN106232625B (zh) 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
BR112016021576A2 (pt) 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
MX355107B (es) 2014-06-03 2018-04-04 Xbiotech Inc Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus.
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
PT3280441T (pt) 2015-04-07 2021-11-30 Alector Llc Anticorpos anti-sortilina e métodos para a sua utilização
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
BR112019005449A2 (pt) 2016-09-20 2019-10-01 Aronora Inc anticorpos inovadores contra fator xi e usos dos mesmos

Also Published As

Publication number Publication date
KR20210021124A (ko) 2021-02-24
AU2020210233A1 (en) 2020-08-20
CR20180583A (es) 2019-07-02
NZ786448A (en) 2025-06-27
TWI752964B (zh) 2022-01-21
MX2023012740A (es) 2024-02-23
NZ748743A (en) 2025-06-27
CA3172367A1 (en) 2017-12-21
JP7277500B2 (ja) 2023-05-19
NZ786442A (en) 2025-06-27
CN116425879A (zh) 2023-07-14
AU2017286432A1 (en) 2018-12-06
US20200317811A1 (en) 2020-10-08
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
CO2018013434A2 (es) 2018-12-28
TW202214702A (zh) 2022-04-16
PE20190416A1 (es) 2019-03-19
CA3025869C (en) 2025-10-07
KR102218714B1 (ko) 2021-02-24
US11485794B2 (en) 2022-11-01
US20200270364A1 (en) 2020-08-27
US11479615B2 (en) 2022-10-25
JP2019521978A (ja) 2019-08-08
TN2018000417A1 (en) 2020-06-15
WO2017218371A1 (en) 2017-12-21
US20200255542A1 (en) 2020-08-13
CN109476758A (zh) 2019-03-15
AR108717A1 (es) 2018-09-19
KR102379580B1 (ko) 2022-03-29
AU2024201084A1 (en) 2024-03-14
CL2018003565A1 (es) 2019-03-22
TW201802120A (zh) 2018-01-16
US11661460B2 (en) 2023-05-30
US20170355780A1 (en) 2017-12-14
US12275800B2 (en) 2025-04-15
JOP20180121A1 (ar) 2018-12-12
IL263272A (en) 2018-12-31
SG10202103120UA (en) 2021-05-28
NZ786447A (en) 2025-06-27
NZ786444A (en) 2025-06-27
GEP20227382B (en) 2022-05-25
UA129793C2 (uk) 2025-08-06
CA3025869A1 (en) 2017-12-21
AU2020210233B2 (en) 2024-03-07
KR20190018504A (ko) 2019-02-22
TWI802193B (zh) 2023-05-11
JP7022081B2 (ja) 2022-02-17
MY201852A (en) 2024-03-20
IL263272B2 (en) 2025-07-01
EP3469002A1 (en) 2019-04-17
SG11201810763TA (en) 2018-12-28
JP2021101720A (ja) 2021-07-15
BR112018075858A2 (pt) 2019-04-02
NZ786443A (en) 2025-06-27
AU2017286432B2 (en) 2020-09-24
US20200308302A1 (en) 2020-10-01
US11512142B2 (en) 2022-11-29
PH12018502586A1 (en) 2019-10-07
MA45234A (fr) 2019-04-17
ECSP18091593A (es) 2019-01-31
MX2018015757A (es) 2019-05-30
IL263272B1 (en) 2025-03-01
EA201892716A1 (ru) 2019-05-31
CN109476758B (zh) 2023-05-23
CL2024000367A1 (es) 2024-08-23
NI201800134A (es) 2019-03-05
IL315266A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
CL2024000367A1 (es) Anticuerpos antifactor de la coagulación xi.
MX2018008939A (es) Anticuerpos anti-factor de la coagulacion xi.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA202091540A1 (ru) Антитела к lilrb2
EA202092435A2 (ru) Моноклональные антитела против bcma
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
GT201500317A (es) Composiciones y métodos para alterar la señalizacion del segundo mensajero
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
SA518400237B1 (ar) SIRPa أجسم مضادة لـ جديدة وتطبيقاتها العلاجية
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MX374286B (es) Compuestos organolepticos novedosos.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
MX374569B (es) Compuestos organolépticos novedosos.
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
MX380297B (es) Compuestos organolépticos novedosos.
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.
TR201401753A2 (tr) Nekroz tedavisine yönelik bir kompozisyon.